NO20083851L - Anvendelse av E09 og propylenglykol ved fremstilling av et medikament til behandling av blaerekreft - Google Patents

Anvendelse av E09 og propylenglykol ved fremstilling av et medikament til behandling av blaerekreft

Info

Publication number
NO20083851L
NO20083851L NO20083851A NO20083851A NO20083851L NO 20083851 L NO20083851 L NO 20083851L NO 20083851 A NO20083851 A NO 20083851A NO 20083851 A NO20083851 A NO 20083851A NO 20083851 L NO20083851 L NO 20083851L
Authority
NO
Norway
Prior art keywords
bladder cancer
propylene glycol
medicament
manufacture
treatment
Prior art date
Application number
NO20083851A
Other languages
English (en)
Inventor
Luigi Lenaz
Guru Reddy
Dorla Mirejovsky
Original Assignee
Spectrum Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spectrum Pharmaceuticals Inc filed Critical Spectrum Pharmaceuticals Inc
Publication of NO20083851L publication Critical patent/NO20083851L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/396—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having three-membered rings, e.g. aziridine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/66—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving luciferase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Genetics & Genomics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Beskrevet heri er ulike blærekreftbehandlinger og fremgangsmåter. Den foreliggende beskrivelsen kan ta fordel av propylenglykolkonsentrasjoner og/eller NAD(P)H:quinon oksidoreduktase-1 (NQOl), Cytokrom P450 Oksidoreduktase (P450R) og Glukose transportanordning 1 (Glut-1) proteinekspresjon i human overgangscellecarcinoma av blæren for å tilby individuelt målrettede blærekreftbehandlinger.
NO20083851A 2006-02-09 2008-09-08 Anvendelse av E09 og propylenglykol ved fremstilling av et medikament til behandling av blaerekreft NO20083851L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77167806P 2006-02-09 2006-02-09
PCT/US2007/061951 WO2007092964A1 (en) 2006-02-09 2007-02-09 Bladder cancer treatment by using e09 and propylene glycol

Publications (1)

Publication Number Publication Date
NO20083851L true NO20083851L (no) 2008-11-10

Family

ID=38055337

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083851A NO20083851L (no) 2006-02-09 2008-09-08 Anvendelse av E09 og propylenglykol ved fremstilling av et medikament til behandling av blaerekreft

Country Status (13)

Country Link
US (3) US20070203112A1 (no)
EP (2) EP1986640A1 (no)
JP (4) JP2009526085A (no)
KR (1) KR101364322B1 (no)
CN (1) CN101384255A (no)
AU (1) AU2007213476B2 (no)
BR (1) BRPI0707563A2 (no)
CA (2) CA2638026C (no)
IL (1) IL193238A (no)
NO (1) NO20083851L (no)
RU (1) RU2396953C2 (no)
WO (2) WO2007092964A1 (no)
ZA (1) ZA200806765B (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002350115A1 (en) 2001-11-01 2003-05-12 Spectrum Pharmaceuticals, Inc. Medical compositions for intravesical treatment of bladder cancer
US8563592B2 (en) * 2001-11-01 2013-10-22 Spectrum Pharmaceuticals, Inc. Bladder cancer treatment and methods
JP5360609B2 (ja) * 2008-09-03 2013-12-04 国立大学法人 東京大学 低酸素環境測定用試薬
US8685010B2 (en) * 2008-11-24 2014-04-01 Gradiant Research, Llc Photothermal treatment of soft tissues
US20110190749A1 (en) 2008-11-24 2011-08-04 Mcmillan Kathleen Low Profile Apparatus and Method for Phototherapy
WO2010102099A1 (en) 2009-03-04 2010-09-10 Gradiant Research, Llc Method and apparatus for cancer therapy
WO2012009382A2 (en) * 2010-07-12 2012-01-19 The Regents Of The University Of Colorado Molecular indicators of bladder cancer prognosis and prediction of treatment response
WO2012040492A1 (en) * 2010-09-22 2012-03-29 The Board Of Regents Of The University Of Texas System Methods of treating cancer comprising targeting nqo1
EP2624777B1 (en) 2010-10-07 2019-03-20 Gradiant Research, Llc Apparatus for skin cancer thermal therapy
GB201021494D0 (en) * 2010-12-20 2011-02-02 Univ Cardiff Compounds
WO2014062856A1 (en) 2012-10-16 2014-04-24 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
JP6615746B2 (ja) * 2013-04-09 2019-12-04 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ 腫瘍選択的併用療法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4898729A (en) * 1983-12-09 1990-02-06 Euroceltique, S.A. Treatment of hypertension, compounds and compositions for antihypertension and diuresis
US5550110A (en) * 1992-04-22 1996-08-27 Warner-Lambert Company Endothelin Antagonists II
US5811416A (en) * 1994-06-06 1998-09-22 Board Of Regents The University Of Texas System Endothelin antagonist and/or endothelin synthase inhibitor in combination with a progestin, an estrogen, a cyclooxygenase inhibitor, or a nitric acid donor or substrate
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US6156744A (en) * 1998-03-19 2000-12-05 Cancer Research Campaign Tech (London) DT-diaphorase directed anti-tumor agents
WO2002049630A2 (en) * 2000-12-21 2002-06-27 Bristol-Myers Squibb Company Method for preventing or treating pain by administering an endothelin antagonist
AU2002350115A1 (en) 2001-11-01 2003-05-12 Spectrum Pharmaceuticals, Inc. Medical compositions for intravesical treatment of bladder cancer
WO2003092731A1 (en) * 2002-05-03 2003-11-13 Novo Nordisk A/S Stabilised solid compositions of modified factor vii
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
CA2502848C (en) * 2002-10-24 2012-10-02 The Board Of Trustees Of The University Of Illinois Use of irl-1620 and paclitaxel for preventing and treating breast tumors
RU2423381C2 (ru) * 2005-07-25 2011-07-10 Трабьон Фармасьютикалз, Инк. Снижение количества в-клеток с использованием cd37-специфических и cd20-специфических связывающих молекул

Also Published As

Publication number Publication date
WO2007092963A1 (en) 2007-08-16
US20090163570A1 (en) 2009-06-25
BRPI0707563A2 (pt) 2011-05-10
EP1986641A1 (en) 2008-11-05
JP2009527470A (ja) 2009-07-30
RU2008136191A (ru) 2010-03-20
US20070203112A1 (en) 2007-08-30
EP1986640A1 (en) 2008-11-05
CA2641617A1 (en) 2007-08-16
CA2638026C (en) 2015-11-24
RU2396953C2 (ru) 2010-08-20
CN101384255A (zh) 2009-03-11
WO2007092964A1 (en) 2007-08-16
IL193238A0 (en) 2009-02-11
JP5457036B2 (ja) 2014-04-02
JP2010116416A (ja) 2010-05-27
AU2007213476A1 (en) 2007-08-16
US20070185188A1 (en) 2007-08-09
KR101364322B1 (ko) 2014-02-18
AU2007213476B2 (en) 2013-03-28
JP2009526085A (ja) 2009-07-16
JP2013107905A (ja) 2013-06-06
ZA200806765B (en) 2009-05-27
KR20080096671A (ko) 2008-10-31
CA2638026A1 (en) 2007-08-16
IL193238A (en) 2015-02-26

Similar Documents

Publication Publication Date Title
NO20083851L (no) Anvendelse av E09 og propylenglykol ved fremstilling av et medikament til behandling av blaerekreft
NO20090887L (no) Fremgangsmate for behandling og forebygging av mukositt
ATE509663T1 (de) Ballon-brachytherapie-applikator
NO20061325L (no) Kombinasjon av legemidler for behandling av neoplasmer
MX2023006561A (es) Formulaciones farmaceuticas transdermicas que comprenden cbd o thc para el tratamiento del cancer.
WO2007111866A3 (en) Combinations of hcv protease inhibitor(s) and cyp3a4 inhibitor(s), and methods of treatment related thereto
WO2006076506A3 (en) Treating a diseased nail
WO2008112565A3 (en) Method and composition for treating cancer
BR0309890A (pt) Composição farmacêutica contendo plasma sanguìneo, ou soro sanguìneo utilizada no tratamento de lesões, bem como seu método e processo de aplicação
WO2008045559A3 (en) Methods of treating oral mucositis
Colucci et al. Vitiligo: an update on current pharmacotherapy and future directions
WO2007049098A3 (en) Therapeutic formulations for the treatment of beta-amyloid related diseases
WO2008022345A3 (en) Compositions and methods for inhibiting cytochrome p450
WO2007037653A8 (en) Use of mesenchymal stem cells genetically modified to express a suicide gene for treating a cancer
MXPA05004697A (es) Soluciones farmaceuticas que comprenden un compuesto modafinil y uso para la fabricacion de un medicamento para tratar diferentes enfermedades.
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
MX2010004350A (es) Metodos de uso del acido (+)-1,4-dihidro-7-[(3s,4s)]-3-metoxi-4-(m etilamino)-1-pirrolidinil-4-oxo-1-(2-tiazolil)-1, 8-naftiridina-3-carboxilico en terapias de combinacion.
BRPI0517976A (pt) métodos de tratamento
Clark et al. Intralesional injection for inflammatory nail diseases
WO2011022633A3 (en) Method of threating cancer
WO2004010934A3 (en) Methods for the use of neurotoxin in the treatment of urologic disorders
Gupta et al. Autologous melanocyte transfer via epidermal grafts for lip vitiligo
TW200511999A (en) Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone
WO2009047505A3 (en) Dexanabinol with inhibitors of braf or mek for the treatment of melanoma
WO2008060535A3 (en) Use of reversine and analogs for treatment of cancer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application